Vaxil Bio Ltd. (TSXV:VXL)
Canada · Delayed Price · Currency is CAD 0.1500
0.00 (0.00%)
At close: Sep 14, 2026
| Market Cap | 597.60K +28.3% |
| Revenue (ttm) | n/a |
| Net Income | 379.00K |
| EPS | 0.11 |
| Shares Out | 3.98M |
| PE Ratio | 1.38 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504 |
| Open | 0.1500 |
| Previous Close | 0.1500 |
| Day's Range | 0.1500 - 0.1500 |
| 52-Week Range | 0.1300 - 0.2900 |
| Beta | -0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Vaxil Bio
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada. [Read more]
Industry Biotechnology
Sector Healthcare
Founded 2006
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol VXL
Financial Performance
Financial StatementsNews
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private...
9 months ago - GlobeNewsWire
Vaxil Announces Non-Brokered Private Placement
NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company intends to complete a non-brokered private p...
10 months ago - GlobeNewsWire